Danish firm Axellia Pharmaceuticals will use its newly acquired majority stake in Phoenix Global Supply Group to launch private-label OTCs in the U.S. and Canada. The Copenhagen-based firm manufactures anti-infective active pharmaceutical ingredients and intends to provide APIs, such as bacitracin and polymyxin B sulfate, for Phoenix to use in topical first-aid products. Axellia said May 18 its investment in White Plains, N.Y.-based Phoenix allows the "significant expansion of Axellia's presence in the international pharmaceutical market.
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?